Polymer(Korea) (폴리머)

The Polymer Society of Korea (한국고분자학회)
권호 표지
DOI QR코드

DOI QR Code

Preparation and Characterization of Solid Dispersions of Eprosartan Using Spray Drying Method

분무 건조 방식으로 제조한 에프로살탄 고체분산체 제조 및 특성 분석

  • Hwang, Jun Seok (Department of Polymer Science and Engineering, Chungnam National University) ;
  • Kim, So Hee (Department of Polymer Science and Engineering, Chungnam National University) ;
  • Cho, Sun Hang (Research Center for Medicinal Chemistry, Division of Drug Discovery Research, Korea Research Institute of Chemical Technology) ;
  • Huh, Kang Moo (Department of Polymer Science and Engineering, Chungnam National University)
  • 황준석 (충남대학교 고분자공학과) ;
  • 김소희 (충남대학교 고분자공학과) ;
  • 조선행 (한국화학연구원 의약화학연구센터) ;
  • 허강무 (충남대학교 고분자공학과)
  • Received : 2012.12.31
  • Accepted : 2013.02.05
  • Published : 2013.07.25
Download PDF
⟨ Previous Next ⟩

Abstract

In this study, we developed and optimized hydrophilic polymer-based solid dispersion formulations (SDs) using a spray drying method for improving the aqueous solubility of eprosartan, one of poorly soluble drugs that has been broadly used for the treatment of high blood pressure. Hydroxylpropylcellulose (HPC) and poly(vinyl pyrrolidone) (PVP) were used as hydrophilic polymer matrices and poloxamer 407 (P407) added as a polymeric surfactant. Various kinds of solid dispersions with different drug/polymer compositions were prepared and their physico-chemical properties were compared. As the polymer content increased, the drug crystallinity in the SDs significantly decreased and the dissolution properties were enhanced. The PVP based SDs were observed to have relatively reduced crystallinity and an enhanced dissolution rate than HPC-based SDs, due to better miscibility between drug and polymer matrix. For PVP based SDs, the drug crystallinity almost disappeared and the dissolution properties significantly increased by more than 3~7 times.

본 연구에서는 분무건조방법을 이용하여 고혈압 치료제로 사용되고 있는 난용성 약물인 에프로살탄의 고체분산체 제형을 다양한 조성 하에서 제조 및 평가하고, 효과적인 약물의 용해도 향상을 위한 제조 조건을 최적화하였다. 친수성 고분자 기제로 hydroxylpropylcellulose(HPC)와 poly(vinyl pyrrolidone)(PVP)를 사용하였고, 고분자 계면활성제로 poloxamer 407을 첨가하여 약물과 고분자의 다양한 조성비를 갖는 고체분산체를 제조한 후, 물리화학적 특성을 비교 평가하였다. 친수성 고분자의 조성비 증가와 함께 약물 결정성이 감소되었으며, HPC보다는 PVP가 약물과의 우수한 상용성을 바탕으로 결정화도 감소와 용출거동 개선 효과가 상대적으로 우수하였다. 친수성 고분자로 PVP를 사용한 경우 약물의 결정성이 대부분 사라져 고체분산체 내 대부분의 약물 분자들이 무정형으로 분산되어 있으며 약물의 용출률이 에프로살탄 대비 3~7배 이상 향상되었다.

Keywords

Acknowledgement

Supported by : 한국연구재단

References

  1. T. M. Allen and P. P. Cullis, Science, 303, 1818 (2004). https://doi.org/10.1126/science.1095833
  2. M. Sugarwara, S. Kadomura, and X. He, Eur. J. Pharm. Sci., 26, 1 (2005). https://doi.org/10.1016/j.ejps.2005.02.017
  3. J. W. Wong and K. H. Yuen, Int. J. Pharm., 227, 177 (2001). https://doi.org/10.1016/S0378-5173(01)00796-7
  4. S. R. Vippagunta, K. A. Maul, and S. Tallavajhala, Int. J. Pharm., 236, 111 (2002). https://doi.org/10.1016/S0378-5173(02)00019-4
  5. M. Martinez, G. Amidon, L. Clarke, W. W. Jones, A. Mitra, and J. Riviere, Adv. Drug Deliv. Rev., 54, 825 (2002). https://doi.org/10.1016/S0169-409X(02)00071-6
  6. M. Vasanthavada, W. Q. Tong, and Y. Joshi, Pharm. Res., 21, 1598 (2004). https://doi.org/10.1023/B:PHAM.0000041454.76342.0e
  7. S. R. Vippagunta, W. Zeren, and S. Hornung, J. Pharm. Sci., 96, 294 (2007). https://doi.org/10.1002/jps.20754
  8. S. L. Lin and J. Menig, J. Pharm. Sci., 57, 2143 (1968). https://doi.org/10.1002/jps.2600571225
  9. J. L. Ford, Pharm. Acta Helvetiae, 61, 69 (1986).
  10. C. Leuner and J. Dressman, Eur. J. Pharm. Biopharm., 50, 47 (2000). https://doi.org/10.1016/S0939-6411(00)00076-X
  11. E. Y. Lee, M. J. Oh, S. Kim, K. Y. Seong, Y. H. Lee, S. J. Kim, H. S. She, D. Lee, and G. Khang, Polymer(Korea), 35, 113 (2011).
  12. G. Khang, J. K. Jeong, J. M. Rhee, J. S. Jee, and H. B. Lee, Macromol. Chem. Symp., 14, 123 (2001).
  13. J. M. Aceves, R. Cruz, and E. Hernandez, Int. J. Pharm., 195, 45 (2000). https://doi.org/10.1016/S0378-5173(99)00303-8
  14. M. O. Omelczuk, C. C. Wang, and D. G. Pope, Eur. J. Pharm. Biopharm., 148, 123 (1997).
  15. A. Billon, B. Bataille, G. Cassanas, and M. Jacob, Int. J. Pharm., 203, 159 (2000). https://doi.org/10.1016/S0378-5173(00)00448-8
  16. N. Zerrouk, C. Chemtob, P. Arnaud, and S. Toscani, Int. J. Pharm., 225, 46 (2001).
  17. E. Karavas, G Ktistis, and A Xenakis, Eur. J. Pharm. Biopharm., 63, 103 (2006). https://doi.org/10.1016/j.ejpb.2006.01.016
  18. E. Merisko-Liversidge and G. G. Liversidge, Adv. Drug Deliv. Rev., 63, 427 (2011). https://doi.org/10.1016/j.addr.2010.12.007
  19. R. Shegokar and R. H. Muller, Int. J. Pharm., 339, 129 (2010).
  20. N. H. Shusterman, Am. Heart J., 138, 238 (1999). https://doi.org/10.1016/S0002-8703(99)70316-9
  21. A. H. Gradman, J. Gray, F. Maggiacomo, H. Punzi, and W. B. White, Clincal Ther., 21, 442 (1999). https://doi.org/10.1016/S0149-2918(00)88300-9
  22. D. V. Drooge, W. Hinrichs, M. Visser, and H. Frijlink, Int. J. Pharm., 310, 220 (2006). https://doi.org/10.1016/j.ijpharm.2005.12.007
  23. A. Goldberg, M. Gibaldi, J. Kanig, and M. Mayersohn, J. Pharm. Sci., 55, 581 (1966). https://doi.org/10.1002/jps.2600550610
  24. T. Vilhelmsen, H. Eliasen, and T. Schaefer, J. Pharm. Sci., 303, 132 (2005).
  25. N. Tsapis, E. R. Dufresne, S. S. Sinha, C. S. Riera, J. W. Hutchinson, L. Mahadevan, and D. A. Weitz, Phys. Rev. Lett., 94, 018302 (2005). https://doi.org/10.1103/PhysRevLett.94.018302

Cited by

  1. 클로피도그렐 황산수소염 고체분산체의 특성 및 용출률 개선 vol.42, pp.2, 2018, https://doi.org/10.7317/pk.2018.42.2.275